Eli Lilly Set to Report Third-Quarter Earnings Driven by Obesity and Diabetes Drugs
Eli Lilly is scheduled to release its third-quarter financial results this Thursday. Market expectations are centered on the continued strong performance of its blockbuster weight-loss drug, Zepbound, and its diabetes medication, Mounjaro. Analysts are projecting earnings per share of $6.26 on revenue of approximately $22.61 billion. Beyond existing blockbusters, investors are closely monitoring the commercial progress of Foundayo, an obesity pill launched in April, with sales estimates hovering around $229 million. Despite facing challenges such as lower net prices in the U.S., Lilly continues to leverage its market dominance against rival Novo Nordisk to fund aggressive expansion through strategic acquisitions in the psychedelics and vaccine sectors.
Topics: diabetes medication earnings preview obesity drugs pharmaceuticals
Part of the story Merck and Eli Lilly Prepare for Third-Quarter Earnings Reports (6 articles)